| 73.51 -1.17 (-1.57%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 90.53 | 1-year : | 105.74 |
| Resists | First : | 77.51 | Second : | 90.53 |
| Pivot price | 71.58  |
|||
| Supports | First : | 66.9 | Second : | 60.34 |
| MAs | MA(5) : | 74.31 |
MA(20) : | 70.98 |
| MA(100) : | 69.3 |
MA(250) : | 51.1 |
|
| MACD | MACD : | 1 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 74 |
D(3) : | 81.7 |
| RSI | RSI(14): 55.2 |
|||
| 52-week | High : | 84.55 | Low : | 26.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ APGE ] has closed below upper band by 28.4%. Bollinger Bands are 29.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 74.24 - 74.65 | 74.65 - 74.98 |
| Low: | 70.38 - 70.88 | 70.88 - 71.29 |
| Close: | 72.74 - 73.52 | 73.52 - 74.17 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Thu, 12 Mar 2026
Barclays PLC Buys 33,494 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
Tue, 10 Mar 2026
A Look At Apogee Therapeutics (APGE) Valuation After Wider Losses And A New Shelf Registration - Sahm
Tue, 10 Mar 2026
Wedbush Raises Price Target on Apogee Therapeutics (APGE) - Finviz
Fri, 06 Mar 2026
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares - MarketBeat
Mon, 02 Mar 2026
APOGEE THERAPEUTICS ($APGE) Releases Q4 2025 Earnings - Quiver Quantitative
Mon, 02 Mar 2026
Decoding Apogee Therapeutics Inc (APGE): A Strategic SWOT Insigh - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 5.9 (%) |
| Held by Institutions | 125.5 (%) |
| Shares Short | 8,700 (K) |
| Shares Short P.Month | 8,090 (K) |
| EPS | -4.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.2 % |
| Return on Equity (ttm) | -31.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -227 (M) |
| Levered Free Cash Flow | -139 (M) |
| PE Ratio | -16.79 |
| PEG Ratio | 0 |
| Price to Book value | 5.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|